Expanding Horizons: Top-tier US Lab Set to Initiate nonclinical In-vivo Research Services in Australia
Melbourne, April 17, 2024 - In a significant stride towards global outreach and enhanced service provision, Attentive Science, a leader in nonclinical In-vivo pharmacokinetics, toxicology and safety pharmacology assays, proudly announces its expansion into the vibrant market of Australia. With a relentless commitment to excellence and a proven track record in delivering cutting-edge solutions, this expansion marks a pivotal moment in the company's journey towards providing unparalleled nonclinical research services worldwide.
Australia, renowned for its thriving healthcare sector and clinical trial ecosystem, presents an opportune landscape for Attentive Science to extend its world-class expertise and state-of-the-art technologies. Leveraging over 20 combined decades of experience in the field, Attentive Science is poised to bring its industry-leading methodologies, unwavering dedication to quality, and commitment to client satisfaction to the Australian shores.
Dr. Alfred Botchway, Board Chair, Attentive Science Australia said, “Today marks a significant milestone as we welcome our new CEO, Holly Stefl, to the team. I am excited about the impact she will have on our performance, underscoring the company's dedication to driving success and value for our clients, employees, and shareholders. We are thrilled to embark on this new chapter as we extend our footprint into Australia. With our expansion into this dynamic market, we are committed to upholding the same rigorous GLP standards of excellence and unwavering dedication to quality that have become synonymous with Attentive Science. We look forward to forging lasting partnerships and contributing to advancements in nonclinical In-vivo research in Australia."
Holly’s leadership will empower Attentive Science to cater to the diverse needs of clients across the globe, offering a comprehensive suite of in-vivo solutions encompassing pharmacokinetics, toxicology and safety pharmacology services utilizing a range of test systems for the completion of late-stage discovery to IND enabling research programs. By establishing a local presence in Australia, Attentive Science aims to foster closer collaborations with emerging biopharma and assist our clients who leverage Australia’s 43.5% R&D tax incentive and streamlined regulatory process.
“I am honored to step into this role as CEO, Attentive Science Australia. It is a privilege to grow a talented team as I am passionate about supporting Australia's vibrant clinical trial ecosystem and making a meaningful impact in this region with Attentive Science depth of scientific expertise,” said Holly Stefl, CEO Attentive Science Australia.
The expansion into Australia aligns with Attentive Science's overarching mission to support the development of cures and remedies to achieve healthier outcomes globally. By harnessing the latest technological innovations and adhering to the highest industry standards, the company remains steadfast in its commitment to delivering defendable, reliable data to the Australian Therapeutic Goods Administration (TGA), U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) that empower informed decision-making in a timely manner.
As Attentive Science prepares to commence operations in Australia, clients can expect a seamless expansion and continued access to the unparalleled expertise and personalized service that have become hallmarks of the Attentive Science brand. Through strategic investments in talent, infrastructure, and technology, Attentive Science is poised to become a strategic partner for In-vivo solutions in the international market.
For more information about Attentive Science and its range of In-vivo solutions and test systems please visit attentivescience.com.
About Attentive Science
Your Mission | Our Research | Healthier Outcomes
Attentive Science is an AAALAC accredited global leader of nonclinical nonGLP and GLP Pharmacokinetic, Toxicology and Safety Pharmacology services to the biotech, pharmaceutical and animal health industry. With a proven track record of scientific excellence, Attentive Science is committed to delivering reliable, defendable data and personalized service to clients worldwide. With over 20 decades of combined veteran scientific experience and expertise with various types of test articles, test systems, route of administration and overall conduct of non-clinical studies, Attentive Science remains at the forefront of innovation, harnessing cutting-edge technologies and industry-leading methodologies to empower critical decision-making milestones.
Contact Us
www.attentivescience.com